image

Welcome to Remedium Bio Corporate News and Investor Information!

Remedium is a Boston based pre-clinical stage Biotechnology company driven by a single basic principle - we believe that any disease can be cured. In line with this principle, Remedium strives to develop life-changing therapeutics for a broad range of diseases, one treatment at a time - a brilliant today for a better tomorrow.

Remedium Corporate News

Explore the latest news, press releases, and investor tools below!

  • Remedium enters collaboration with leading Rheumatology laboratory - 09/21

    BOSTON, Sep 15, 2021 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts University’s foremost Rheumatology laboratory to complete pre-clinical efficacy studies on Remedium’s lead gene therapy candidate, a single-injection potentially disease-modifying Osteoarthritis treatment. The research is being led by Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine, whose laboratory has developed in vitro, ex vivo, and in vivo testing capabilities for Osteoarthritis (OA). Dr. Zeng is well-known for her extensive expertise in preclinical Rheumatology. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

    “The initiation of this research program is a significant milestone for Remedium, and will provide compelling data on our unique approach to the treatment of Osteoarthritis” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium aims to characterize the functionality of its lead candidate in a range of in vitro, ex vivo, and in vivo efficacy models that will help advance its lead candidate toward IND readiness”.

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium invited to present at China Focus 2021 - 08/21

    BOSTON, Aug 11, 2021 - Remedium Bio, Inc. is excited to announce that the company has been invited to present at the 2021 China Focus Online Roadshow (CFOR). The China Focus event is sponsored by the Jiangsu Industrial Technology Research Institute (JITRI), which is a conglomerate of 39 specialty research institutes and a home to over 260 start-ups. With over 10,000 potential business partners, China Focus brings together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross border investment and collaboration in leading biopharma innovations. "We are excited to have been invited to present at CFOR 2021, this is a unique opportunity to present Remedium to a premier panel of investors" said Frank Luppino, President and CEO of Remedium Bio, "Remedium's business model is based on the application of proven technologies in novels ways to treat diseases with well-characterized pathology, creating value for investors rapidly and efficiently - CFOR 2021 is a perfect opportunity to validate this business model with the global investment community."

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium selected to present at the Digital RESI 2021 Pitch Challenge - 08/21

    BOSTON, Aug 2, 2021 - Remedium Bio is excited to announce that the company has been selected to present at the Digital RESI 2021 Innovator's Pitch Challenge. Redefining Early Stage Investments (RESI) conference series is a multi-day investment event that brings together over 450 investors and leading Start-Up Fundraising Executives. This year's digital venue will be held virtually on September 13-15, 2021. RESI, a product of Life Science Nation LLC, is a unique and versatile tool for sourcing deals and advancing innovation across early-stage life science, biotechnology, and healthcare. "We are extremely excited to be selected to present at RESI, this is further validation of the significant market need addressed by Remedium's lead product candidates" said Frank Luppino, CEO of Remedium Bio. Remedium will showcase the lead product candidate and discuss the broad applicability of its modular product development approach.

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium appoints Dr Tim McAlindon as Scientific and Medical Advisor - 07/21

    BOSTON, Jul 12, 2021 - Remedium is excited to announce that Dr. Timothy McAlindon, MD, MPH is serving as a scientific and medical advisor for the company’s Rheumatology portfolio. Dr. McAlindon is the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. He is a recognized Key Opinion Leader in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in of Medicine and Bachelor of Medicine from the University of Southhampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London, and the Royal United Hospital in the UK. Tim is board certified in Internal Medicine and Rheumatology and is a recipient of a number of prestigious honors and awards including Top Doctor from Boston Magazine and the U.S. News & World Report, 2018 Distinguished Clinical Research Achievement Award from the Clinical Research Forum, as well as the ACR REF Amgen Wyeth Rheumatology Fellowship Training Award. Dr. McAlindon is an author of numerous scientific publications in a broad range of high-impact factor journals including the Journal of the American Medical Association (JAMA) and Annals of Internal Medicine with a research focus in Rheumatoid and Osteoarthritis. "We are extremely excited to partner with Dr. Tim McAlindon in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Tim is a world-renowned authority who brings a wealth of scientific, regulatory, and clinical experience that enables further validation of our exciting pipeline".

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium selected to present at the Unicorn Cup Finals - 07/21

    BOSTON, Jul 8, 2021 - Remedium is excited to announce that the company has been selected to present at the Unicorn Cup Finals on July 15, 2021. The Unicorn Cup is the world's largest start-up pitch contest attended by over 1000 premier Venture Capital firms and Angel Investors. From a long list of applicants, 7 companies were selected to present at the North America cup on July 8, 2021, and only 2 companies were selected to advance to the Unicorn Cup Finals representing North America. According to the Startup Network, the organizer of the event, winners of the Unicorn Cup have raised over $296 million in funding. "This is an incredible opportunity to further validate Remedium's business model and our ability to provide significant value to our investors" said Frank Luppino, President and CEO of Remedium. "We are extremely excited to have been selected to present Remedium at the North America Cup, and now to be one of only two companies selected to represent North America at the Unicorn Cup Finals".

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium appoints Dr Anastassios Pittas as Scientific and Medical Advisor - 06/21

    BOSTON, Jun 30, 2021 - Remedium Bio, Inc. is extremely excited to announce that Dr. Anastassios Pittas will serve as a Scientific and Medical Advisor on the company’s Endocrinology portfolio. Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism and Professor of Medicine at Tufts University. He is a recipient of a number of prestigious honors and awards including multiple consecutive Top Doctor awards from Boston Magazine, Biomedical Research Exemplar Award which honors individuals doing high-quality, high-impact, federally-funded research who also maintain an impressive reputation for professionalism and integrity in their work as well as the Donna Seto-Young Award, which recognizes meritorious achievement in the advancement of science, education, practice of medicine or improvement of human health and well-being. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center. "Partnering with Dr. Pittas brings significant subject matter expertise in Endocrinology and helps Remedium validate its multiple Diabetes pipeline candidates from a clinical perspective" said Frank Luppino, CEO of Remedium Bio. "We are extremely excited to be working with Dr. Pittas and are looking forward to evaluating our novel and proprietary approaches to treating Type 1 and Type 2 diabetes with gene therapy".

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium Bio appoints Alex Goraltchouk as Chief Operating Officer - 06/21

    BOSTON, Jun 11, 2021 - Remedium Bio, Inc. is excited to announce the appointment of Alex Goraltchouk as the Chief Operating Officer. Alex brings 16 years industry experience developing and industrializing biologics and gene therapies at companies including Allergan, Biogen, and Regeneron. Alex’s experience, which ranges from start-up to Fortune 500 spans the development, industrialization, and launch of a number of market-dominant brands including Spinraza (SMA antisense oligonucleotide), Benepali (TNF inhibitor), Kevzara (IL-6 inhibiting monoclonal antibody), and Praluent (PCSK9 inhibiting monoclonal antibody). With a focus on endocrinology, rheumatology, and cardiovascular diseases, Alex’s functional expertise allow the company to further strengthen the R&D, Operations, Quality, and Project Management organizations. Holding a Bachelor in Materials Engineering and a Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida, Alex possesses a broad scientific background in several disciplines that add significant value to Remedium’s development efforts. Alex is a Cornell certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, a Bioinformatics MicroMasters from the University of Maryland University College, a Stanford Certificate in Genetics and Genomics, and is a Certified Project Management Professional enabling the company’s scientific advancement and operational efficiency. “I am delighted to welcome Alex to Remedium” said Frank Luppino, Remedium’s President and CEO. “Alex has broad technical capabilities and demonstrated leadership experience that align perfectly with Remedium’s mission to develop novel gene therapies for diseases with significant unmet needs.”

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium Bio, Inc. secures Seed Round of financing - 04/21

    BOSTON, Apr 16, 2021 - Remedium Bio, Inc. a Boston based biotechnology company focused on developing curative therapies in a broad range of diseases, announced today the funding of the Seed Series Financing round, raising over $1.2 million to build out the management team and advance the lead candidate molecules through pre-clinical efficacy.

    With this financing, Remedium shareholders will benefit from significant value creation via the advancement of multiple molecules through discovery and pre-clinical development within the company's core platforms including gene delivery, growth factor expression, and disease reversal. Proceeds from Remedium's financing will be used to initiate operations, secure key leadership personnel, complete in vitro and in vivo efficacy studies for our lead program, and initiate in vitro efficacy for the second pipeline candidate. Further to the addition of top talent to Remedium's team, the company will use the funds to secure key strategic partnerships with academic institutions and suppliers, hire a world-renowned scientific advisory board, and support a number of IND-enabling studies.

    "We are highly excited about securing this financing for Remedium, a foundational investment which will enable the company to build the infrastructure and create the data to validate the pre-clinical biology of our lead candidates," said Frank Luppino, President and CEO of Remedium Bio, Inc.

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium to present at the 2020 Octane OC LaunchPad Investment Forum - 10/20

    BOSTON, Sep 3, 2020 - Remedium Bio, Inc. is excited to be selected as the LaunchPad Finalist at the Octane OC MedTech Innovation Forum, 2020. "We are delighted to have been invited to present in the Octane OC MedTech Innovation Forum 2020 as part of the finalist companies! This is indeed a high vote of confidence for our technology and business model." - said Frank Luppino, President and CEO of Remedium Bio. "Our mission to cure dibilitating diseases by combining proven therapeutic modalities in a novel, innovative approach presents a unique opportunity for our shareholders and potential investors; we are excited to share our progress to date at the Octane OC 2020 forum!". Remedium Bio, a Boston based gene therapy start-up, is focused on developing curative therapies in a broad range of diseases is advancing it's lead candidate toward IND-readiness in 2022.

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

  • Remedium Bio appoints Frank Luppino as President and CEO - 01/20

    BOSTON, Jan 9, 2020 - Remedium Bio, Inc. is delighted to announce the appointment of Frank Luppino as President and Chief Executive Officer, Treasurer and Chairman of the Board starting Jan 10, 2020. Mr. Luppino brings over 25 years product development, industrialization, and commercial launch experience at public and private companies including Anika Therapeutics, Bionostics, and Black & Veatch. Serving as the Chief Operating Officer at Anika Therapeutics, Frank has extensive demonstrated experience leading R&D, Operations, Regulatory, Clinical, and Supply Chain organizations. Further to his broad cross-functional expertise, Frank was instrumental at leading the launch of a series of blockbuster biologic, cell therapy, and drug-device combination products including CingalTM, MonoviscTM, HyalofastTM, and TactosetTM. Finally, Frank’s experience spans a broad range of therapeutic areas including rheumatology, soft tissue regeneration, and ophthalmology, bringing significant business, technical, clinical, and regulatory expertise to the company.

    “Remedium is at an exciting, foundational stage of its corporate evolution, with a highly innovative pipeline of disruptive, curative therapies, Remedium is well positioned to successfully advance these high-value product candidates to the clinic and beyond, creating value for our shareholders,” said Mr. Luppino. “I look forward to building the Remedium team and advancing our lead candidates through pre-clinical development and driving business value creation.” 

    Contact Remedium: info@remedium-bio.com
    Source: Remedium Bio, Inc.

investor faq

  • what we do
    Remedium bio at a glance

    Remedium Bio, Inc. is a biotechnology company focused on the development of curative therapies for a broad range of pathologies. Our people passionately believe that any disease can be cured and are tirelessly working to deliver therapies to patients for a broad range of therapeutic categories. Grounded in our premise, Remedium scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues one treatment at a time.

    Our team is located in the Boston area, a modern-day Mecca of Biotechnology. We are founded on the vision of changing lives via curative breakthroughs with a firm scientific foundation with the goal of creating a company that changes the way we think about treating disease.

  • our people
    our people - the remedium team

    Our people are at the core of everything we do, they are what makes Remedium special, what makes our innovations unique, the driving force behind our vision that any disease can be cured. With this in mind, Remedium strives to hire the most talented professionals in the industry, the brightest minds with the most open hearts - adventurers with an inner child, glass half full, looking at the world through rose colored glasses.

    As a company we firmly believe in diligently and persistently investing in our people, supporting training, education, and growth, every step of their way. Inclusion and diversity are at our core, acceptance of all cultures and ideas is the Remedium gold standard, and it is upon this edifice that we venture to build a company to cure one disease at a time - a brilliant today for a better tomorrow.

  • our science
    the ideas that drive our therapies

    Science is at the foundation of everything we do at Remedium - a uniting principle that innovation, data-driven analysis, and a culture conducive to open discussion that promotes a healthy debate is essential to ideation and delivery of the ideas as treatments to patients. At the core of our values are the principles that all decisions should be supported by data, all scientific ideas are worthy of careful consideration, and turning ideas into medicine is the most noble pursuit of humanity.

  • ethical commitment
    A HIGH ETHICAL AND SOCIAL BAr

    At Remedium, we are firmly committed to upholding the highest ethical standards including integrity, honesty and truthfulness, multicultural and intellectual diversity, respect for all ideas and individuality, inclusion, transparency, freedom of expression, and respect for the dignity and rights of all individuals. Furthermore, we strive to achieve the highest standards in Corporate Social Responsibility and create a sustainable future for our People, Community, and Environment.

    Remedium and our highly-valued team strives to exercise this commitment in everything we do. As members of the Biotechnology community we feel a heightened need to hold ourselves to the highest standards of ethical responsibility in addition to fully abiding by international, federal, and state laws and regulations, following internal policies and industry best practices wherever and whenever possible.

Background Image

remedium bio

Learn more about why we believe that any disease can be cured.

about us

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!


1116 Great Plain Ave, Suite 203
Needham, MA
02492


E: info@remedium-bio.com
P: +1 (978) 467 5217